YHGJ exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9, indicating fundamental weakness across almost all health metrics. The company is currently loss-making with a negative ROE of -26.27% and a catastrophic 1-year price decline of 71.7%. While the Price/Sales ratio is low (0.35), the lack of earnings growth and a high PEG ratio (6.22) suggest a value trap rather than a bargain. The combination of negative net margins and a failing technical trend makes this a high-risk asset.